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Abstract
Recombinant rat interleukin (IL)-5-induced prolongation of rat eosinophil survival in culture was inhibited in a
concentration-dependent manner by the protein synthesis inhibitor cycloheximide, the DNA-dependent RNA synthesis
inhibitor actinomycin D, and the tyrosine kinase inhibitor herbimycin A when examined 96 h after incubation. The MEK-1
inhibitor PD98059 inhibited IL-5-induced phosphorylation of both p44 and p42 MAP kinases, but the IL-5-induced
prolongation of eosinophil survival was not inhibited. In contrast, the JAK2 inhibitor AG490 inhibited the IL-5-induced
prolongation of eosinophil survival. Treatment of eosinophils with IL-5 resulted in phosphorylation of STAT5 but
not STAT1, and the IL-5-induced phosphorylation of STAT5 was inhibited by AG490. These findings suggest that
the activation of JAK2 tyrosine kinase and protein synthesis are required for the prolongation of rat eosinophil survival
induced by recombinant rat IL-5. STAT5 phosphorylation might also participate in the IL-5-induced survival of rat
eosinophils. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Allergic in£ammations including bronchial asthma
and atopic dermatitis are associated with the accu-
mulation and activation of granulocytes, particularly
eosinophils [1]. In such diseases, the number of eo-
sinophils is increased in the bone marrow, blood and
in£ammatory sites [2^4]. In the in£ammatory site,
in¢ltrating eosinophils release mediators such as
superoxide anion, arachidonic acid metabolites and
granule proteins including major basic protein, eosin-
ophil cationic protein, eosinophil-derived neurotoxin
and eosinophil peroxidase by various stimuli, and
contribute to tissue damage [5^8].
Interleukin (IL)-5 is a cytokine responsible for the
proliferation, di¡erentiation, and activation of eosin-
ophils [9^12]. IL-5 exerts its biological activities after
binding to the IL-5 receptor consisting of the IL-5-
speci¢c K subunit and the common L subunit, the
latter being common to the receptors for IL-5, IL-3
and granulocyte-macrophage colony stimulating fac-
tor (GM-CSF) [13,14]. After binding of IL-5 to its
receptor, tyrosine kinases such as Janus protein ki-
nase (JAK) 1, JAK2 and Lyn are rapidly phosphor-
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ylated [15^21], and these tyrosine kinases contribute
to propagation of a JAK/signal transducer and acti-
vator of transcription (STAT) signaling pathway [19^
21] and a p44/42 mitogen-activated protein (MAP)
kinase signaling pathway [16] in human blood eosin-
ophils.
Eosinophil survival-enhancing activity is one of
the activities of IL-5 in humans, mice, and rats
[10,11,22]. It is reported that IL-5 prolongs human
eosinophil survival by abrogating apoptosis [22,23].
It is suggested that the anti-apoptotic e¡ect of IL-5
on human eosinophils is dependent on JAK2 activa-
tion, RNA synthesis and protein synthesis [17,22].
However, the signal transduction pathway for IL-5-
induced prolongation of eosinophil survival has not
been clari¢ed in detail.
Rats are widely used for the analysis of allergic
in£ammation [24^28]. However, the analysis of par-
ticipation of eosinophils in allergic in£ammation in
rats remains to be clari¢ed. Recently, we have pre-
pared recombinant rat IL-5 using the baculovirus
expression system from hemolymph of silkworm
Bombyx mori larvae [11], and shown that the re-
combinant rat IL-5 possesses eosinophil di¡erentia-
tion factor activity, B cell growth factor II activity,
and eosinophil survival-enhancing factor activity
[11,12]. In the present study, we have analyzed the
possible signal transduction pathway for the prolon-
gation of rat eosinophil survival induced by recombi-
nant rat IL-5.
2. Materials and methods
2.1. Materials
Recombinant rat IL-5 was prepared as described
previously [11]. Cycloheximide and actinomycin D
were purchased from Wako (Osaka, Japan). Herbi-
mycin A ((15R)-17-demethoxy-15-methoxy-11-O-
methyl-gledanamycin) was from Research Biochemi-
cals (Natick, MA, USA). PD98059 (2P-amino-3P-
methoxy£avone) was obtained from New England
Biolabs (Beverly, MA, USA). AG490 (2-cyano-3-
(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propena-
mide) was purchased from Sigma (St. Louis, MO,
USA). Reagents were dissolved in dimethyl sulfox-
ide. Recombinant rat IL-5 was dissolved in phos-
phate-bu¡ered saline (PBS) containing 0.1% (w/v)
bovine serum albumin (BSA, Sigma). An aliquot of
each solution was added to the medium, and the ¢nal
concentration of the vehicle in the medium was ad-
justed to 0.1% (v/v). The control medium contained
the same amount of the vehicle.
2.2. Preparation of rat eosinophils
Preparation of rat peritoneal eosinophils was car-
ried out according to our previous reports [29,30]. In
brief, male rats of the Sprague-Dawley strain (specif-
ic pathogen-free, weighing 500^550 g, Charles River,
Kanagawa, Japan) received an oral administration of
cyclophosphamide (Sigma) suspended in 0.5% (w/v)
sodium carboxymethylcellulose (Wako) at a dose of
100 mg/kg on day 0. Ascaris suum extract (Greer
Laboratories, Lenoir, NC, USA) as an antigen,
8 mg protein aliquot, was suspended in 1 ml saline
containing 10 mg aluminum hydroxide (Wako) as an
adjuvant. On day 2, as an immunization, 0.1 ml of
the antigen suspension was injected intradermally at
two nuchal and three lumbar sites, and 0.5 ml of the
same solution was injected intraperitoneally. On day
12, a 5 mg protein aliquot of the antigen in 0.5 ml
saline containing 5 mg aluminum hydroxide was in-
jected intraperitoneally as a booster injection. Fi-
nally, on day 19, 30 ml of saline containing an 8 mg
protein aliquot of the antigen was injected intraper-
itoneally. After 48 h, the rats were killed by cutting
the carotid artery under diethyl ether anesthesia.
Then, the peritoneal cells were collected, layered on
discontinuous Percoll (Sigma) gradients (density:
1.080 and 1.100 g/ml), and centrifuged at 1000Ug
and 4‡C for 30 min. The fraction between the two
layers containing eosinophils was collected and
washed three times with ice-cold PBS. The purity
of eosinophils was more than 95% as assessed by
May-Gru«nwald-Giemsa staining, and the viability
of eosinophils was more than 98% by Trypan blue
exclusion test. The rats were treated in accordance
with procedures approved by the Animal Ethics
Committee of the Graduate School of Pharmaceuti-
cal Sciences, Tohoku University, Sendai, Japan.
2.3. Determination of survival of rat eosinophils
The puri¢ed peritoneal eosinophils were seeded in
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each well of the 96-well plates (Falcon 3075, 96 £at-
bottom wells, Becton Dickinson, Oxnard, CA, USA)
at a density of 1U105 cells in 0.1 ml of RPMI 1640
medium (Gibco-BRL, Gaithersburg, MD, USA) sup-
plemented with 10% (v/v) fetal bovine serum (FBS,
Flow Laboratories, North Rydge, NSW, Australia)
containing 100 pM recombinant rat IL-5 in the pres-
ence or absence of various concentrations of drugs
and incubated at 37‡C for 96 h. After incubation, the
viability of eosinophils was determined by the ability
to exclude Trypan blue dye. The viability of eosino-
phils was calculated from the following equation:
viability (%) = (number of cells that excluded Trypan
blue dye/number of total cells)U100.
2.4. Flow cytometric analysis for eosinophil apoptosis
Flow cytometric analysis was performed to identi-
fy apoptosis of eosinophil according to the method
described by Nicoletti et al. [31] with slight modi¢-
cations. After incubation, eosinophils were ¢xed in
70% (v/v) ethanol at 320‡C for 4 h, and centrifuged
at 500Ug and 4‡C for 5 min. The precipitated eosin-
ophils were suspended in the permeability bu¡er
(0.192 M sodium phosphate and 4 mM citric acid),
and incubated at room temperature for 30 min. After
centrifugation at 500Ug and 4‡C for 5 min, the pre-
cipitate was suspended in PBS containing 0.1 mg/ml
RNase (Toyobo, Osaka, Japan) and incubated at
37‡C for 30 min. Then, the cell suspension was cen-
trifuged at 500Ug and 4‡C for 5 min, and the pre-
cipitate was suspended in PBS containing 50 Wg/ml
propidium iodide (Wako), and incubated at room
temperature for 30 min. DNA contents in eosino-
phils were analyzed by FACScan (Becton Dickin-
son).
2.5. Immunoblotting
The cells were lysed for 30 min in ice-cold lysis
bu¡er (25 mM Tris-HCl, pH 7.4, 25 mM NaCl,
25 mM glycerol, 1% (v/v) Triton X-100, 50 mM so-
dium £uoride, 25 mM p-nitrophenyl phosphate,
1 mM phenylmetylsulfonyl £uoride, 1 mM sodium
orthovanadate, 10 Wg/ml leupeptin, 10 mM sodium
pyrophosphate, and 10 nM okadaic acid). After cen-
trifugation of the cell lysate at 18 600Ug and 4‡C for
20 min, the supernatant fraction was subjected to
electrophoresis on 7.5% (w/v) acrylamide gel at 125
V for 2 h, and the separated proteins in the gel were
transferred to a nitrocellulose membrane and
blocked in the blocking solution (Block Ace, Dainip-
pon, Osaka, Japan) for 1 h at room temperature. To
detect phosphorylated p44/42 MAP kinases, phos-
phorylated STAT1, and phosphorylated STAT5,
the nitrocellulose membrane was incubated for 12 h
at 4‡C with the rabbit anti-phospho-p44/42 MAP ki-
nase (Thr202/Tyr204) polyclonal antibody (New
England Biolabs), the goat anti-phospho-STAT1
(Tyr701) polyclonal antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), the rabbit anti-phos-
pho-STAT1 (Ser727) polyclonal antibody (Santa
Cruz Biotechnology), and the rabbit anti-phospho-
STAT5 (Tyr695) polyclonal antibody (New England
Biolabs), respectively. Thereafter, the membrane was
incubated for 3 h at 4‡C with the biotinylated anti-
rabbit IgG (Vector Laboratories, Burlingame, CA,
USA) or the biotinylated anti-goat IgG (Vector Lab-
oratories). The reaction products were incubated at
room temperature for 30 min with Vectastain ABC
reagent (Vector Laboratories) and visualized by the
chemiluminescence detection system (ECL Systems,
Amersham, Arlington Heights, IL, USA). The mem-
brane was exposed to a Kodak X-Omat AR ¢lm
(Eastman Kodak, Rochester, NY, USA). To detect
p44/42 MAP kinases, STAT1, and STAT5, the mem-
brane was stripped by incubation in 62.5 mM Tris-
HCl, pH 6.7, 2% (w/v) sodium dodecyl sulfate, and
100 mM 2-mercaptoethanol at 50‡C for 30 min, then
incubated with the rabbit anti-rat MAP kinase R2
(ERK1-CT) polyclonal antibody (Upstate Biotech-
nology, Lake Placid, NY, USA), the mouse anti-
STAT1K p91 (C-111) monoclonal antibody (Santa
Cruz Biotechnology), and the rabbit anti-STAT5b
(C-17) polyclonal antibody (Santa Cruz Biotechnol-
ogy), respectively, and further incubated with the
phosphatase-labeled anti-rabbit IgG (Kirkegaad p
Perry Laboratories, Gaithersburg, MD, USA) or
the phosphatase-labeled anti-mouse IgG (Kirkegaad
p Perry Laboratories) as described above. The reac-
tion products on membrane were visualized by BCIP/
NBT color substrate (Promega, Madison, WI, USA).
The phosphorylated STAT1 was also detected by
mobility shift of STAT1 using the mouse anti-
STAT1K p91 (C-111) monoclonal antibody as de-
scribed above.
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2.6. Statistical analysis
The statistical signi¢cance of the results was ana-
lyzed by Dunnett’s test for multiple comparison.
3. Results
3.1. E¡ects of IL-5 on eosinophil survival
When rat eosinophils were incubated at 37‡C, the
viability of eosinophils was decreased time-depen-
dently. A signi¢cant decrease in viability was ob-
served after 24 h (Fig. 1A). In contrast, when eosin-
ophils were incubated in the presence of 100 pM IL-
5, the viability of eosinophils was not decreased so
prominently as that of the control eosinophils till 96
h (Fig. 1A). A signi¢cantly higher viability of IL-5-
treated eosinophils than of control eosinophils was
observed at 24, 48, 72, and 96 h (Fig. 1A). Flow
cytometric analysis revealed that the eosinophil apo-
ptosis was inhibited by 100 pM IL-5 when deter-
mined 72 h after incubation (Fig. 1B^E). These
¢ndings indicate that recombinant rat IL-5 prolongs
the survival of rat eosinophils by inhibiting apopto-
sis.
3.2. E¡ects of cycloheximide and actinomycin D on
IL-5-induced prolongation of eosinophil survival
When eosinophils were incubated at 37‡C for 96 h
in the presence of 100 pM IL-5 and various concen-
trations of cycloheximide (Fig. 2A) or actinomycin D
(Fig. 2B), the IL-5-induced prolongation of eosino-
phil survival was inhibited in a concentration-depen-
dent manner. Both cycloheximide at 360 nM and
actinomycin D at 80 nM inhibited the IL-5-induced
prolongation of eosinophil survival to almost the
basal level (Fig. 2A,B). In the absence of IL-5, the
viability of eosinophils was not a¡ected by cyclohex-
imide (360 nM) (Fig. 2A) and actinomycin D (80 nM)
(Fig. 2B), indicating that the decrease in the IL-5-
induced prolongation of eosinophil survival by cyclo-
heximide or actinomycin D is not due to the cytotox-
icity of these compounds. These ¢ndings suggest that
protein synthesis is required for the expression of
IL-5-induced prolongation of rat eosinophil survival.
Fig. 1. E¡ects of IL-5 on eosinophil survival. (A) Eosinophils
(1U105 cells) were incubated at 37‡C for the periods indicated
in 0.1 ml of RPMI 1640 medium supplemented with 10% (v/v)
FBS in the presence (b) or absence (a) of 100 pM IL-5. The
viability of eosinophils was determined by the ability to exclude
Trypan blue dye. Values are the means from ¢ve samples.
S.E.M. is within each symbol. Statistical signi¢cance:
**P6 0.01, ***P6 0.001 vs. 0 h; and P6 0.01, and P6 0.001
vs. corresponding control. (B^E) Eosinophils (1U106 cells) were
incubated at 37‡C for 72 h in 1 ml of RPMI 1640 medium sup-
plemented with 10% (v/v) FBS in the presence (D) or absence
(C) of 100 pM IL-5. Eosinophil apoptosis was assessed by £ow
cytometry using propidium iodide before incubation (B) or 72 h
after incubation (C,D). The percentage of apoptotic cells calcu-
lated by £ow cytometry is indicated in B^D, and represented as
a histogram (E). Values are the means þ S.E.M. from three
samples. Statistical signi¢cance: ***P6 0.001 vs. before incuba-
tion, ###P6 0.001 vs. 72 h after incubation without IL-5.
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3.3. E¡ects of herbimycin A, a tyrosine kinase
inhibitor, on IL-5-induced prolongation of
eosinophil survival
To analyze the implication of tyrosine kinases in
the IL-5-induced prolongation of eosinophil survival,
eosinophils were incubated at 37‡C for 96 h in the
presence of 100 pM IL-5 and various concentrations
of the tyrosine kinase inhibitor herbimycin A. As
shown in Fig. 3, the IL-5-induced prolongation of
eosinophil survival was inhibited by herbimycin A
in a concentration-dependent manner. In the absence
of IL-5, the viability of eosinophils was not a¡ected
Fig. 3. E¡ects of herbimycin A on IL-5-induced prolongation
of eosinophil survival. Eosinophils (1U105 cells) were incubated
at 37‡C for 96 h in 0.1 ml medium with or without 100 pM
IL-5 and the indicated concentrations of herbimycin A (HM
A). The viability of eosinophils was determined by the ability
to exclude Trypan blue dye. Values are the means from ¢ve
samples with S.E.M. shown by vertical bars. Statistical signi¢-
cance: ***P6 0.001 vs. 0 pM IL-5; ###P6 0.001 vs. 100 pM
IL-5 without HM A.
Fig. 2. E¡ects of cycloheximide and actinomycin D on IL-5-in-
duced prolongation of eosinophil survival. Eosinophils (1U105
cells) were incubated at 37‡C for 96 h in 0.1 ml medium with
or without 100 pM IL-5 and the indicated concentrations of cy-
cloheximide (CHX) (A) or actinomycin D (AM D) (B). The vi-
ability of eosinophils was determined by the ability to exclude
Trypan blue dye. Values are the means from ¢ve samples with
S.E.M. shown by vertical bars. Statistical signi¢cance:
**P6 0.01, ***P6 0.001 vs. 0 pM IL-5; ###P6 0.001 vs.
100 pM IL-5 without CHX or AM D.
Fig. 4. Time course of IL-5-induced phosphorylation of p44/
p42 MAP kinases in eosinophils. Eosinophils (2U106 cells)
were incubated at 37‡C for the periods indicated in 2 ml me-
dium with or without 100 pM IL-5. The cells were lysed and
phosphorylated p44/42 MAP kinases (upper panel) and p44/42
MAP kinases (middle panel) were detected by immunoblotting.
The phosphorylated p44/42 MAP kinases and p44/42 MAP ki-
nases were quanti¢ed by scanning densitometry. The density ra-
tio of phosphorylated p44 MAP kinase to p44 MAP kinase
(closed column) and that of phosphorylated 42 MAP kinase to
p42 MAP kinase (open column) are shown in the lower panel.
The mean density ratio at time 0 min is expressed as 1.0. Val-
ues are the means from three samples with S.E.M. shown by
vertical bars. Statistical signi¢cance: *P6 0.05, **P6 0.01,
***P6 0.001 vs. 0 min.
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by herbimycin A (100 nM) (Fig. 3), indicating that
the decrease in the IL-5-induced prolongation of eo-
sinophil survival by herbimycin A is not due to the
cytotoxicity of herbimycin A. These ¢ndings suggest
that the activation of tyrosine kinases is necessary for
the IL-5-induced prolongation of eosinophil survival.
3.4. IL-5-induced phosphorylation of p44/42 MAP
kinases and e¡ects of PD98059 on IL-5-induced
prolongation of eosinophil survival
Treatment of eosinophils with 100 pM IL-5 in-
duced time-dependent phosphorylation of p44 and
p42 MAP kinases (Fig. 4). Maximal phosphorylation
of the two MAP kinases was observed at 15 min and
it decreased at 30 min (Fig. 4). In contrast, when
eosinophils were incubated in the absence of 100
pM IL-5, no phosphorylation of p44 and p42 MAP
kinases was detected during the 30 min incubation
(Fig. 4). The maximal phosphorylation of p44 and
p42 MAP kinases at 15 min induced by 100 pM IL-5
was inhibited by the MEK1 inhibitor PD98059 in a
concentration-dependent manner, when eosinophils
were preincubated for 30 min at 37‡C in medium
containing various concentrations of PD98059 (Fig.
5). However, as shown in Fig. 6, PD98059 at 1^30
WM did not inhibit the IL-5-induced prolongation of
eosinophil survival at 96 h. These ¢ndings suggest
that the phosphorylation of p44/p42 MAP kinases
is not involved in the IL-5-induced prolongation of
eosinophil survival.
3.5. E¡ects of AG490, a JAK2 inhibitor, on
IL-5-induced prolongation of eosinophil survival
When eosinophils were incubated at 37‡C for 96 h
in the presence of 100 pM IL-5 and various concen-
trations of the JAK2 inhibitor AG490, the IL-5-in-
duced prolongation of eosinophil survival was inhib-
ited in a concentration-dependent manner (Fig. 7).
Fig. 5. E¡ects of PD98059 on IL-5-induced phosphorylation of
p44/42 MAP kinases in eosinophils. Eosinophils (2U106 cells)
were preincubated at 37‡C for 30 min in 2 ml medium contain-
ing the indicated concentrations of PD98059. The cells were
further incubated at 37‡C for 15 min in the presence or absence
of 100 pM IL-5 and the continuing presence of the indicated
concentrations of PD98059. The cells were lysed and phosphor-
ylated p44/42 MAP kinases (upper panel) and p44/42 MAP ki-
nases (middle panel) were detected by immunoblotting. The
phosphorylated p44/42 MAP kinases and p44/42 MAP kinases
were quanti¢ed by scanning densitometry. The density ratio of
phosphorylated p44 MAP kinase to p44 MAP kinase (closed
column) and that of phosphorylated p42 MAP kinase to p42
MAP kinase (open column) are shown in the lower panel. The
mean density ratio at 0 min is expressed as 1.0. Values are the
means from three samples with S.E.M. shown by vertical bars.
Statistical signi¢cance: **P6 0.01, ***P6 0.001 vs. 100 pM IL-
5 without PD98059; ###P6 0.001 vs. 0 pM IL-5 without
PD98059. The two columns on the left represent the cells that
were preincubated at 37‡C for 30 min in the presence or ab-
sence of 30 WM PD98059, and the levels of phosphorylated
p44/42 MAP kinases and p44/42 MAP kinases.
Fig. 6. E¡ects of PD98059 on IL-5-induced prolongation of eo-
sinophil survival. Eosinophils (1U105 cells) were incubated at
37‡C for 96 h in 0.1 ml medium with or without 100 pM IL-5
and the indicated concentrations of PD98059. The viability of
eosinophils was then determined by the ability to exclude Try-
pan blue dye. Values are the means from ¢ve samples with
S.E.M. shown by vertical bars. Statistical signi¢cance:
***P6 0.001 vs. 0 pM IL-5 without PD98059; ###P6 0.001 vs.
100 pM IL-5 without PD98059.
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These ¢ndings suggest that the activation of JAK2 is
implicated in the IL-5-induced prolongation of eosin-
ophil survival.
3.6. E¡ects of IL-5 on phosphorylation of STAT1 and
STAT5 in eosinophils
The phosphorylation of each STAT was assessed
by immunoblotting as an index of the activation of
STAT. When the eosinophils were incubated at 37‡C
for 30 min in the presence of 100 pM IL-5, no mo-
bility shift of STAT1 was observed (Fig. 8). Phos-
phorylation of either the tyrosine residue or the ser-
ine residue on STAT1 was also not observed as
detected by immunoblotting using anti-phosphotyro-
Fig. 7. E¡ects of AG490 on IL-5-induced prolongation of eo-
sinophil survival. Eosinophils (1U105 cells) were incubated at
37‡C for 96 h in 0.1 ml medium with or without 100 pM IL-5
and the indicated concentrations of AG490. The viability of eo-
sinophils was then determined by the ability to exclude Trypan
blue dye. Values are the means from ¢ve samples with S.E.M.
shown by vertical bars. Statistical signi¢cance: *P6 0.05,
***P6 0.001 vs. 0 pM IL-5 without AG490; ###P6 0.001 vs.
100 pM IL-5 without AG490.
Fig. 8. E¡ects of IL-5 on phosphorylation of STAT1 in eosino-
phils. Eosinophils (2U106 cells) were incubated at 37‡C for the
periods indicated in 2 ml medium with or without 100 pM IL-
5. The cells were lysed, and STAT1 and phosphorylated STAT1
were detected by immunoblotting (upper panel). Because
STAT1 was not phosphorylated by IL-5, the density of STAT1
in the cells is shown in the lower panel. The mean density at
time 0 min is expressed as 1.0. Values are the means from three
samples with S.E.M. shown by vertical bars.
Fig. 9. E¡ects of IL-5 on phosphorylation of STAT5 in eosino-
phils. (A) Eosinophils (2U106 cells) were incubated at 37‡C for
the periods indicated in 2 ml medium with or without 100 pM
IL-5. (B) Eosinophils (2U106 cells) were incubated at 37‡C for
15 min in 2 ml medium containing the indicated concentrations
of IL-5. The cells were lysed, and phosphorylated STAT5
(upper panel) and STAT5 (middle panel) were detected by im-
munoblotting. The phosphorylated STAT5 and STAT5 were
quanti¢ed by scanning densitometry, and the density ratio of
phosphorylated STAT5 to STAT5 is shown in the lower panel.
The mean density ratio at time 0 min is expressed as 1.0. Val-
ues are the means from three samples with S.E.M. shown by
vertical bars. Statistical signi¢cance: (A) ***P6 0.001 vs. 0 min;
(B) *P6 0.05, ***P6 0.001 vs. 0 pM IL-5.
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sine STAT1 polyclonal antibody and anti-phospho-
serine STAT1 polyclonal antibody, respectively (data
not shown). In contrast, as determined using an anti-
phospho-STAT5 polyclonal antibody, STAT5 was
phosphorylated in a time-dependent manner follow-
ing stimulation with IL-5 at 100 pM, whereas STAT5
in control eosinophils was not phosphorylated during
the 30 min incubation (Fig. 9A). Maximal phosphor-
ylation of STAT5 was observed 15 min after stimu-
lation with IL-5 (Fig. 9A). Signi¢cant phosphoryla-
tion of STAT5 by IL-5 was observed at 1, 10 and
100 pM (Fig. 9B).
3.7. E¡ects of AG490 on IL-5-induced
phosphorylation of STAT5
When eosinophils were preincubated for 6 h at
37‡C in medium containing various concentrations
of AG490, and further incubated for 15 min at
37‡C in the presence of 100 pM IL-5 and the con-
tinuing presence of AG490, the IL-5-induced phos-
phorylation of STAT5 was inhibited by AG490 at
30 and 100 WM (Fig. 10). Without preincubation,
AG490 showed no e¡ect, and maximal inhibition
was induced with preincubation for over 6 h (data
not shown). These ¢ndings suggest that IL-5 phos-
phorylates STAT5 but not STAT1 in rat eosinophils,
and that STAT5 is phosphorylated by activation of
JAK2 followed by stimulation with IL-5.
3.8. E¡ects of various drugs on IL-5-induced
inhibition of eosinophil apoptosis
Eosinophils were incubated for 72 h at 37‡C in
medium containing 100 pM IL-5 and various drugs,
and the degree of eosinophil apoptosis was examined
by £ow cytometry. As shown in Fig. 11, eosinophil
apoptosis was inhibited by IL-5, and the anti-apo-
ptotic e¡ect of IL-5 on eosinophils was blocked by
cycloheximide (360 nM), actinomycin D (80 nM),
herbimycin A (100 nM), and AG490 (100 WM). How-
ever, PD98059 (30 WM) did not block the anti-apo-
Fig. 10. E¡ects of AG490 on IL-5-induced phosphorylation of
STAT5. Eosinophils (2U106 cells) were preincubated at 37‡C
for 6 h in 2 ml medium containing the indicated concentrations
of AG490 and further incubated at 37‡C for 15 min in the
presence or absence of 100 pM IL-5 and the continuing pres-
ence of the indicated concentrations of AG490. The cells were
lysed, and phosphorylated STAT5 (upper panel) and STAT5
(middle panel) were detected by immunoblotting. The phos-
phorylated STAT5 and STAT5 were quanti¢ed by scanning
densitometry, and the density ratio of phosphorylated STAT5
to STAT5 is shown in the lower panel. The mean density ratio
at 0 min is expressed as 1.0. Values are the means from three
samples with S.E.M. shown by vertical bars. Statistical signi¢-
cance: ***P6 0.001 vs. 100 pM IL-5 without AG490;
###P6 0.001 vs. 0 pM IL-5 without AG490. The two columns
on the left represent the cells that were preincubated at 37‡C
for 6 h in the presence or absence of 100 WM AG490, and the
levels of phosphorylated STAT5 and STAT5.
Fig. 11. E¡ects of various reagents on IL-5-induced inhibition
of eosinophil apoptosis. Eosinophils (1U106 cells) were incu-
bated at 37‡C for 72 h in 1 ml medium in the presence or ab-
sence of 100 pM IL-5 and the indicated concentrations of cy-
cloheximide (CHX), actinomycin D (AM D), herbimycin A
(HM A), PD98059, or AG490. Eosinophil apoptosis was as-
sessed by £ow cytometry using propidium iodide. Values are
the means from three samples. Statistical signi¢cance:
***P6 0.001 vs. None in the presence of 100 pM IL-5.
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ptotic e¡ect of IL-5 (Fig. 11). These ¢ndings suggest
that the IL-5-induced inhibition of eosinophil apo-
ptosis is induced through protein synthesis, and acti-
vation of tyrosine kinases including JAK2 but not
p44/42 MAP kinases.
4. Discussion
The severity of asthma is suggested to be regulated
by IL-5 through eosinophil activation [32^35]. The
prolongation of eosinophil survival induced by IL-5
might be one of the factors that cause eosinophilia in
allergic in£ammations. However, the intracellular
mechanism for the prolongation of eosinophil surviv-
al by IL-5 has not been clari¢ed in detail. In this
study, we found that recombinant rat IL-5 phosphor-
ylates p44/42 MAP kinases (Fig. 4) and STAT5 (Fig.
9) but not STAT1 (Fig. 8) in rat eosinophils. The IL-
5-induced phosphorylation of p44/42 MAP kinases
and STAT5 is reduced by the MEK1 inhibitor
PD98059 (Fig. 5) and the JAK2 inhibitor AG490
(Fig. 10), respectively. The prolongation of eosino-
phil survival by IL-5 correlates with the inhibition of
eosinophil apoptosis (Figs. 1 and 11). Both the IL-5-
induced prolongation of eosinophil survival and the
IL-5-induced inhibition of eosinophil apoptosis are
suppressed by the protein synthesis inhibitor cyclo-
heximide (Figs. 2A and 11), the DNA-dependent
RNA synthesis inhibitor actinomycin D (Figs. 2B
and 11), the tyrosine kinase inhibitor herbimycin A
(Figs. 3 and 11), and the JAK2 inhibitor AG490
(Figs. 7 and 11), but they are not a¡ected by the
MEK1 inhibitor PD98059 (Figs. 6 and 11).
It is reported that p44/42 MAP kinases in eosino-
phils are activated or phosphorylated by IL-4, IL-5,
GM-CSF, platelet-activating factor, or leukotriene
B4 [16,17,36^38]. Pazdrak et al. [17] reported that
the antisense oligodeoxynucleotide of raf-1, which
is a signaling pathway upstream from MEK in p44/
42 MAP kinases, abrogates IL-5-induced prolonga-
tion of human eosinophil. However, it has not been
clari¢ed whether the activation of p44/42 MAP ki-
nases participates in IL-5-induced prolongation of
eosinophil survival. In this study, we showed that
the prolongation of rat eosinophil survival by IL-5
was not inhibited by the MEK1 inhibitor PD98059
at 30 WM, although IL-5-induced phosphorylation of
p44/42 MAP kinases was inhibited at this concentra-
tion of PD98059 (Figs. 5, 6 and 11). Our ¢ndings
suggest that the anti-apoptotic e¡ect of raf-1 is inde-
pendent of the activation of p44/42 MAP kinases.
Similar observations have been reported recently by
Miike et al. [36]. They indicated that phosphoryla-
tion of p44/42 MAP kinases does not participate in
GM-CSF-stimulated human eosinophil survival.
Therefore, it is possible that the activation of p44/
42 MAP kinases is not involved in IL-5- or GM-
CSF-induced prolongation of eosinophil survival.
A JAK/STAT signaling pathway, which is trig-
gered by various cytokines, is one of the signaling
pathways in the regulation of cell functions [39]. In
eosinophils, it is reported that JAK1, JAK2, STAT1
and STAT5 are activated by stimulation with IL-5 or
GM-CSF [15^21,36]. JAK2 is suggested to play a
critical role in the prolongation of eosinophil survival
induced by IL-5 or GM-CSF in humans, because the
JAK2 inhibitor AG490 reduced the prolongation of
eosinophil survival induced by these cytokines
[17,36]. It is reported that JAK2 activates STAT
and the signal transducing adaptor molecule
(STAM), and these molecules participate in the
JAK/STAT pathway and the JAK/STAM pathway,
respectively [39,40]. However, the targeting molecule
of JAK2 in IL-5-induced prolongation of eosinophil
survival has not been clari¢ed. Nor has it been clari-
¢ed whether JAK2 phosphorylated by IL-5 activates
STAT1 or STAT5, and whether activation of
STAT1, STAT5 or both is necessary for the IL-5-
induced prolongation of eosinophil survival. In the
present study, we examined the e¡ect of IL-5 on
STAT1 phosphorylation till 30 min after incubation,
because Pazdrak et al. [19] reported that phosphory-
lation of STAT1 was detected 15 and 30 min after
IL-5 stimulation at 100 pM in human eosinophils.
However, in rat eosinophils, no mobility shift of
STAT1 was induced by 100 pM IL-5 up to 30 min
(Fig. 8). Furthermore, immunoblotting using anti-
bodies to tyrosine-phosphorylated STAT1 and ser-
ine-phosphorylated STAT1 revealed that neither the
residues of tyrosine nor those of serine on STAT1
were phosphorylated by IL-5 (data not shown). In
the present study, we therefore concluded that
STAT1 is not phosphorylated by IL-5 in rats. How-
ever, there is a discrepancy between our results in rat
eosinophils and those described by Pazdrak et al. [19]
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and Bruggen et al. [21] in human eosinophils. They
reported that STAT1 is phosphorylated by IL-5 in
human eosinophils. Further investigation is necessary
to clarify whether there exist species di¡erences in
STAT1 phosphorylation by IL-5 in eosinophils.
In rats, STAT5 was dramatically phosphorylated
by IL-5 in a time- and concentration-dependent man-
ner (Fig. 9), and the IL-5-induced phosphorylation
of STAT5 was blocked by AG490 (Fig. 10). Further-
more, the IL-5-induced prolongation of eosinophil
survival was inhibited by AG490 (Figs. 7 and 11).
The ¢ndings that the inhibition of JAK2 activation
reduces both the IL-5-induced phosphorylation of
STAT5 and the IL-5-induced prolongation of eosin-
ophil survival suggest that the activation of STAT5
but not STAT1 through the activation of JAK2 plays
a role in the IL-5-induced prolongation of eosinophil
survival.
In eosinophil survival and signal transduction by
IL-5 in rats and by GM-CSF in humans [36], there
are the following four common phenomena: (1) p44/
42 MAP kinases and JAK2 are activated, (2) the
decrease in eosinophil survival by apoptosis is inhib-
ited, (3) the activation of p44/42 MAP kinases is not
implicated in eosinophil survival, and (4) the activa-
tion of JAK2 is implicated in the survival of eosino-
phils. The IL-5 receptor and the GM-CSF receptor
share the common L-chain [14] which is critical for
binding and signaling of IL-5, IL-3 and GM-CSF
[41,42]. Van Dijk et al. [42] reported that the deletion
mutant of the cytoplasmic domain of the common L-
chain failed to activate STAT5 by IL-5, and sug-
gested that the activation of STAT5 is implicated
in the phosphorylation of tyrosine residues of the
common L-chain. Ogata et al. [18] reported that
JAK1 associates with the common L-chain and
JAK2 associates with the IL-5 receptor K-chain.
Although the mechanism of activation of JAK2
through these cytokine receptors has not been clari-
¢ed, the activation of JAK2 seems to play an impor-
tant role in eosinophil survival via these receptors.
As previously reported in human eosinophils [22,23],
protein synthesis is essential for the IL-5-induced
prolongation of eosinophil survival in rats (Figs. 2
and 11). Dibbert et al. [43] reported that Bcl-xL but
not Bcl-2 is expressed in eosinophils incubated with
IL-5 and GM-CSF and that the prolongation of eo-
sinophil survival induced by IL-5 and GM-CSF is
partially inhibited by the antisense oligonucleotide
of Bcl-xL. Moreover, it is reported that the Bcl-xL
gene contains a doublet of functional STAT5 binding
sites in the promoter region [44,45]. Therefore, it is
possible that the JAK2-activated STAT5 contributes
to the induction of certain proteins (e.g. Bcl-xL) that
prolong eosinophil survival. Further investigation is
necessary to clarify whether such proteins are pro-
duced by the signaling pathway of JAK2-activated
STAT5.
In conclusion, recombinant rat IL-5 prolongs rat
eosinophil survival. The IL-5-induced prolongation
of eosinophil survival is mediated by the activation
of tyrosine kinases including JAK2, which activates
STAT5 but not STAT1. Protein synthesis is also
necessary for the IL-5-induced prolongation of eosin-
ophil survival. It is also suggested that certain pro-
teins produced through the JAK2 signaling pathway,
but not through the p44/42 MAP kinase signaling
pathway, might be critical for the IL-5-induced pro-
longation of eosinophil survival.
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